tetano
Editor, Senior Moderator
Mediterr J Rheumatol
. 2022 Mar 31;33(1):68-74.
doi: 10.31138/mjr.33.1.68. eCollection 2022 Mar.
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
Eleftherios Pelechas[SUP] 1 [/SUP], Vassiliki Drossou[SUP] 1 [/SUP], Paraskevi V Voulgari[SUP] 1 [/SUP], Alexandros A Drosos[SUP] 1 [/SUP]
Affiliations
Abstract
Current data demonstrated that in patients with coronavirus disease-19 (COVID-19), there is a dysregulation of the immune system during the severe form of the disease. This dysregulation is expressed with an uncontrolled release of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-17, tumour necrosis factor alpha (TNFa) and chemokines, associated with increased serum ferritin levels and other acute phase reactants. On the other side, these cytokines play a pivotal role in autoimmune rheumatic diseases (ARD), mostly in rheumatoid arthritis (RA) and the spondyloarthropathies. Patients affected with ARD represent a particular vulnerable group, considering that they may be in an immunocompromised status due to their ailment and its treatment on one side, but on the other side, they may be protected from their immunosuppressive therapy. To this end, we present five patients with RA treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and biologic (b) DMARDs who were affected from COVID-19 and we will try to give answers to the above hypothesis.
Keywords: COVID-19; bDMARDs; csDMARDs; hydroxychloroquine; rheumatoid arthritis; tocilizumab.
. 2022 Mar 31;33(1):68-74.
doi: 10.31138/mjr.33.1.68. eCollection 2022 Mar.
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
Eleftherios Pelechas[SUP] 1 [/SUP], Vassiliki Drossou[SUP] 1 [/SUP], Paraskevi V Voulgari[SUP] 1 [/SUP], Alexandros A Drosos[SUP] 1 [/SUP]
Affiliations
- PMID: 35611100
- PMCID: PMC9092100
- DOI: 10.31138/mjr.33.1.68
Abstract
Current data demonstrated that in patients with coronavirus disease-19 (COVID-19), there is a dysregulation of the immune system during the severe form of the disease. This dysregulation is expressed with an uncontrolled release of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-17, tumour necrosis factor alpha (TNFa) and chemokines, associated with increased serum ferritin levels and other acute phase reactants. On the other side, these cytokines play a pivotal role in autoimmune rheumatic diseases (ARD), mostly in rheumatoid arthritis (RA) and the spondyloarthropathies. Patients affected with ARD represent a particular vulnerable group, considering that they may be in an immunocompromised status due to their ailment and its treatment on one side, but on the other side, they may be protected from their immunosuppressive therapy. To this end, we present five patients with RA treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and biologic (b) DMARDs who were affected from COVID-19 and we will try to give answers to the above hypothesis.
Keywords: COVID-19; bDMARDs; csDMARDs; hydroxychloroquine; rheumatoid arthritis; tocilizumab.